U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1 - 10 of 35 results

structurally diverse
Status:
US Approved Rx (2011)
Source:
BLA125296
(2011)
Source URL:
First approved in 2011
Source:
BLA125296
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Approved Rx (2011)
Source:
BLA125296
(2011)
Source URL:
First approved in 2011
Source:
BLA125296
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT02798406: Phase 2 Interventional Active, not recruiting Brain Cancer
(2016)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03554109: Phase 2 Interventional Withdrawn Triple Negative Breast Cancer (TNBC)
(2018)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT00006106: Phase 1 Interventional Withdrawn Lip and Oral Cavity Cancer
(1999)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03554109: Phase 2 Interventional Withdrawn Triple Negative Breast Cancer (TNBC)
(2018)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03586869: Phase 1/Phase 2 Interventional Active, not recruiting Pancreatic Cancer
(2018)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT01436968: Phase 3 Interventional Recruiting Prostate Cancer
(2011)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03398655: Phase 3 Interventional Recruiting Recurrent Platinum Resistant Ovarian Cancer
(2017)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03190824: Phase 2 Interventional Active, not recruiting Melanoma Stage III
(2016)
Source URL:

Class:
STRUCTURALLY DIVERSE